| |  Online-Ressource |
|---|
| Verfasst von: | Hahn, Michael [VerfasserIn]  |
|---|
| | Böttcher, S. [VerfasserIn] |
|---|
| | Dietrich, Sascha [VerfasserIn] |
|---|
| | Hegenbart, Ute [VerfasserIn] |
|---|
| | Rieger, Michael [VerfasserIn] |
|---|
| | Stadtherr, Peter [VerfasserIn] |
|---|
| | Bondong, Andrea [VerfasserIn] |
|---|
| | Ritgen, Matthias [VerfasserIn] |
|---|
| | Schmitt, Thomas [VerfasserIn] |
|---|
| | Tran, Thuong Hien [VerfasserIn] |
|---|
| | Görner, Martin [VerfasserIn] |
|---|
| | Krämer, Isabelle [VerfasserIn] |
|---|
| | Luft, Thomas [VerfasserIn] |
|---|
| | Schönland, Stefan [VerfasserIn] |
|---|
| | Witzens-Harig, Mathias [VerfasserIn] |
|---|
| | Zenz, Thorsten [VerfasserIn] |
|---|
| | Kneba, Michael [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| Titel: | Allogeneic hematopoietic stem cell transplantation for poor-risk CLL |
|---|
| Titelzusatz: | dissecting immune-modulating strategies for disease eradication and treatment of relapse |
|---|
| Mitwirkende: | Schulz, Renate |
|---|
| Verf.angabe: | M. Hahn, S. Böttcher, S. Dietrich, U. Hegenbart, M. Rieger, P. Stadtherr, A. Bondong, R. Schulz, M. Ritgen, T. Schmitt, T.H. Tran, M. Görner, I. Herth, T. Luft, S. Schönland, M. Witzens-Harig, T. Zenz, M. Kneba, A.D. Ho and P. Dreger |
|---|
| E-Jahr: | 2015 |
|---|
| Jahr: | 6 July 2015 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Gesehen am 17.03.2021 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2015 |
|---|
| Band/Heft Quelle: | 50(2015), 10, Seite 1279-1285 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor lymphocyte infusions) was guided by minimal residual disease (MRD) monitoring and commenced at a median of 91 (22-273) days after alloHCT, resulting in a probability of being event free and MRD-negative 1 year after transplant of 57% (84% in those encountering chronic GvHD). Patients who were event free and MRD-negative at the 12-month landmark had a 4-year PFS of 77% and largely remained durably MRD-negative if MRD clearance had occurred subsequent to immune modulation. Three-year overall survival, PFS, relapse incidence and non-relapse mortality of all 77 patients were 69, 57, 26 and 24%, respectively. Survival was not affected by EBMT risk category but by active disease at alloHCT, which could not be overcome by intensification of conditioning. Twenty-three patients who experienced relapse post alloHCT had a survival of 56% at 2 years after CLL recurrence. In conclusion, MRD-guided immune modulation after alloHCT for high-risk CLL can provide durable MRD clearance in more than half of the patients. |
|---|
| DOI: | doi:10.1038/bmt.2015.150 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/bmt.2015.150 |
|---|
| | Volltext: https://www.nature.com/articles/bmt2015150 |
|---|
| | DOI: https://doi.org/10.1038/bmt.2015.150 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 175159839X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL / Hahn, Michael [VerfasserIn]; 6 July 2015 (Online-Ressource)
